Dimerix Ltd has released a press release.
Last Patient Completes Dosing in DKD Phase 2 Clinical Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Dimerix
- Dimerix Completes $5.8m Placement
- Last Patient Completes Dosing in FSGS Phase 2 Clinical Study
- Global REMAP-CAP Platform Trial Protocol To Include DMX-200
- R&D Tax Incentive Facility
- DMX-200 Treatment Continued Under TGA Special Access Scheme
Later from Dimerix
- Positive Top-Line Results in FSGS Phase 2a Clinical Study
- Dimerix Awarded $1 Million MRFF Funding
- Positive Top-Line Results in DKD Phase 2 Clinical Study
- DMX-700 Data Demonstrates Effect on Key COPD Receptors
- Receipt of R&D Tax Incentive
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix